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ABSTRACT 
 
Background: Liver transplantation is the only life-extending intervention for primary 
sclerosing cholangitis (PSC). Given the co-existence with colitis, patients may also 
require colectomy; a factor potentially conferring improved post-transplant outcomes. 
Aim: Determine the impact of restorative surgery via ileal pouch anal anastomosis 
(IPAA) vs. retaining an end ileostomy on liver-related outcomes post-transplantation. 
Methods: Graft survival was evaluated across a prospectively accrued transplant 
database, stratified according to colectomy status and type. 
Results: Between 1990 and 2016, 240 individuals with PSC/colitis underwent 
transplantation (cumulative 1,870-patient-years until 1
st
 graft loss or last follow-up 
date), of whom 75 also required colectomy. A heightened incidence of graft loss was 
observed for the IPAA group vs. those retaining an end ileostomy (2.8 vs. 0.4 per-
100-patient-years, log-rank P=0.005), whereas rates between IPAA vs. no colectomy 
groups were not significantly different (2.8 vs. 1.7, P=0.1). Additionally, the 
ileostomy group experienced significantly lower graft loss rates vs. patients retaining 
an intact colon (P=0.044). The risks conferred by IPAA persisted when taking into 
account timings of colectomy as relates to liver transplantation via time-dependent 
Cox-regression analysis. Hepatic artery thrombosis and biliary strictures were the 
principal aetiologies of graft loss overall. Incidence rates for both were not 
significantly different between IPAA and no colectomy groups (P=0.092 and 
P=0.358); however, end ileostomy appeared protective (P=0.007 and 0.031, 
respectively). 
Conclusion: In PSC liver transplantation, colectomy+IPAA is associated with a 
similar incidence rate of hepatic artery thrombosis, recurrent biliary strictures and re-
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transplantation compared to no colectomy; whereas colectomy+end ileostomy confers 
more favourable graft outcomes. 
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INTRODUCTION 
 
Primary sclerosing cholangitis (PSC) is a chronic, progressive cholangiopathy for 
which therapy other than liver transplantation is ineffective (1). Whilst PSC is 
considered to be a rare disease (2), it is one associated with significant and 
disproportionate unmet need, wherein ~50% of patients reach a clinical endpoint of 
death or liver transplantation (3,4). Indeed, PSC accounts for >10% of all United 
Kingdom liver transplant activity, whilst also being the lead indication for 
transplantation in Nordic countries (5,6). Although transplantation is a proven life-
extending intervention, the incidence of graft loss is significantly greater compared to 
that observed for non-PSC aetiologies (7). 
 
The vast majority of patients with PSC also develop inflammatory bowel disease 
(IBD) at some point; predominantly colitis phenotypically (3,8). Whilst the clinical 
course of gut and liver disease do not necessarily parallel, a series of epidemiological 
findings indicate that coexistence of colitis is associated with poorer transplant-free 
survival when compared to PSC patients without an inflammatory bowel disease 
history (3,9). Moreover, data from a nationwide observational cohort study in Sweden 
suggests that rates of progression to liver transplantation or death may be lower for 
patients treated with colectomy prior to PSC-diagnosis (10).  
 
Following liver transplantation, colectomy does not appear protective against graft 
per se (11), although data from several centres indicate that retention of an intact 
colon, particularly one associated with ongoing inflammatory activity post-transplant, 
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increases the risk of developing post-transplant complications including disease 
recurrence and hepatic artery thrombosis  (7,12–16).  
 
The definitive, first-line surgical treatment for patients with ulcerative colitis (UC) 
refractory to medical therapy is a subtotal colectomy (17). This can either be 
performed leaving an end ileostomy in situ; or followed by ileorectal anastomosis 
(IRA), or restorative proctocolectomy and ileal-pouch anal anastomosis (IPAA). In 
patients with UC alone, health-related global quality of life is similar for ‘well-
informed’ individuals choosing to retain an ileostomy versus those with a pelvic 
pouch (18,19), the latter being opted for in approximately 30% of cases (20). This rate 
has remained relatively constant over the last decade and outcomes are generally good 
for patients without PSC.  
 
In a Nationwide study from Sweden, the pouch failure rates following restorative 
proctocolectomy were not significantly different between patients with UC alone vs. 
PSC/UC (21); although other investigators have reported consistently poorer 
nocturnal pouch function and worse quality of life scores in the latter group, in 
addition to high rates of recurrent pouchitis, pouch mucosal atrophy and dysplastic 
change (22–24). With respect to the post liver transplant setting, 58% to 62% of 
patients may develop exacerbating features of acute pouchitis (25–27). IRA may also 
not be favoured given the increased risk of rectal cancer associated with PSC 
specifically (28,29).  
 
Whilst the frequency of pouch-related complications is well documented in the PSC 
literature, the impact of IPAA on graft survival following liver transplantation is ill 
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defined. To this effect, we determined the post-transplant clinical course in PSC 
patients with an IPAA; specifically compared to those who elected to retain an end 
ileostomy following their colonic resection, or individuals with colitis yet no 
colectomy. Our aim was to improve the post-transplant survival estimates for patients 
and further understand the recipient risk factors contributing to graft loss. 
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PATIENTS AND METHODS 
 
Study population 
We reviewed a prospectively collected, well-characterised database of all adult 
patients undergoing liver transplantation at the University Hospitals Birmingham 
NHS Foundation Trust from 1990 up to January 2016. The hospital transplant 
database is maintained prospectively, details of which can be found elsewhere (30). 
The immunosuppression protocol for liver transplant recipients across our study 
period is provided in Supplementary Table 1. In order to ensure robustness, 
accuracy and completeness of data, the transplant database was cross-referenced with 
an independently accrued registry of all patients having previously attended or under 
current follow-up of our dedicated PSC clinic. Our intent-to-study population 
comprised all patients undergoing liver transplantation with PSC and colitis 
 
Details pertaining to IBD and colectomy status (including type IPAA or ileostomy) 
were collected retrospectively for individuals having undergone colonic resection 
prior to transplantation, and prospectively in those requiring bowel surgery at any 
point in the post-transplant course. All those with an intact colon underwent at least 
one colonoscopy following liver transplantation. Surveillance colonoscopy continued 
for patients with known colitis, until the point of colectomy or death, in keeping with 
recommended intervals during the era of clinical follow-up (31,32).   
 
Clinical endpoints 
The ‘time-dependent’ primary clinical endpoint for our study was the incidence rate 
of first graft loss (death censored). Given the starting point and prolonged observation 
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period of our study, aetiologies of graft loss were classified broadly, according to 
hepatic artery thrombosis, recurrent biliary stricturing disease in the absence of 
hepatic artery occlusion, graft rejection, and primary graft non-function. Secondary 
endpoints included the incidence rate of recipient mortality, or graft loss / mortality as 
a combined outcome measure. Patients were censored at the date of last follow-up if 
they did not meet the clinical endpoint in question.  
 
Statistical analysis 
Data are presented using the median and interquartile range (IQR) for continuous 
variables. The non-parametric Mann-Whitney U-test was used to determine whether 
significant differences existed between 2 groups, or the Kruskal-Wallis test with 
Bonferroni-Dunn post-hoc correction with >2 groups. Differences in nominal data 
were compared by Fisher’s exact test. A P value of <0.05 was deemed statistically 
significant. Risk stratification as pertains to clinical outcomes’ analysis was 
performed through Kaplan-Meier survivorship estimates, and significant differences 
between groups assessed by Log-rank / Mantel-Cox testing. The proportion of clinical 
events are presented as incidence rates (IR) per 100-patient-years (pt.-yrs.) with 
respective confidence intervals (95% CI). Time zero was set at the point of first liver 
transplantation. Given that colorectal resection may be performed after liver 
transplantation in PSC, the impact of colectomy ‘type’ (IPAA or retaining an end 
ileostomy) was also determined as a time-dependent covariate via Cox regression 
analysis (33). All data were analysed using IBM
®
 SPSS
®
 v.23.0 (Armonk, NY: IBM 
Corp.).  
 
 
 11 
 
Quality control and ethical approval  
Completeness, plausibility and validity of the data were independently verified (by 
PJT, JR and ES), including personalised objective review of all historical medical 
charts. Local regulatory board approval was obtained prior to study initiation and 
database/chart review (CAB-04186-12 and CARMS-02246). 
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RESULTS 
 
Characteristics of the patient population 
Over a 26-year observation period, 240 patients with PSC and colitis underwent liver 
transplantation and comprised our intended study population (175 patients were men; 
median age of the overall cohort at time of transplant of 47 years [IQR 37 – 57 
years]). Across this cohort, we observed 27 incidents of graft loss and 88 recipient 
deaths over time; yielding a cumulative follow-up until re-transplantation or mortality 
of 1,870 patient-years and 2,043 patient-years, respectively (Figure 1).  
 
Colectomy does not protect against liver graft loss or recipient mortality. 
Overall, 31% of patients with PSC and colitis underwent colectomy (n = 75 / 240), 
either prior to or following first liver transplantation, and before reaching the primary 
clinical endpoint. Observing the study cohort in its entirety, the incidence of graft loss 
or patient mortality was no different between the colectomy vs. no colectomy groups 
(Figure 2), even on restricting analysis to those undergoing colonic resection prior to 
liver transplantation (Supplementary Figure 1).  
 
We observed no significant prognostic impact with regard to graft loss conferred by 
male sex, recipient age at time of transplant or at time of colectomy, pre-transplant 
MELD score, era in which transplantation was performed, biliary anastomosis type, 
split liver donation, or organ donation after circulatory death (P value >0.05 for all 
tested covariates). 
 
 
 13 
The incidence of graft loss is increased for patients with IPAA  
Within the colectomy group, 28% (21/75 patients) subsequently underwent creation 
of an IPAA, akin to the rate reported for UC patients overall (20). Formation of IPAA 
was more common when colonic resection took place prior to liver transplantation (n 
= 14/21 vs. 20/54 patients who retained end an ileostomy, P = 0.024), and when 
surgery was performed at a younger age (39 vs. 49 years, P = 0.001; Table 1). 
Overall, 76 patients (32%) developed at least one episode of acute rejection, with no 
significant difference between our 3 study groups (Chi-squared P=0.710). 
 
All 21 patients with an IPAA reported deterioration in symptoms related to pouch 
function, subjectively, within 12 months of liver transplantation. Fifteen/21 patients 
displayed endoscopically and histologically confirmed inflammation during this time; 
and all episodes were acute by definition (34), albeit recurrent at a frequency <3 times 
per year. 
 
Although colectomy overall was not protective, we observed significant differences in 
the incidence of graft loss between the IPAA patient group (IR: 2.8 [95% CI: 2.0 – 
4.5]; 1-, 5-, and 10-year graft loss rates: 85%, 79% and 70%), those without 
colectomy (IR: 1.7 [1.5 – 2.1], 91%, 88% and 88%) and the ileostomy group (IR: 0.4 
[0.3 – 0.5], 1-, 5-, and 10-year graft loss rates: 100%, 98% and 95%) (overall log-rank 
P value between the three groups = 0.038; Figure 3); findings which persisted in sub-
analysis only of patients undergoing colonic resection prior to liver transplantation 
(Supplementary Figure 2).  
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In a direct pairwise comparison, it became apparent that statistically significant 
differences were attributable to improved liver graft survival experienced by the end 
ileostomy group versus patients with an IPAA and compared to the no colectomy 
group (log rank P value = 0.005 and 0.044, respectively) (Figure 3). By contrast, the 
incidence of graft loss was similar between the IPAA group vs. those without 
colectomy (p = 0.1).  
 
However, when evaluating the impact of colectomy type as a time-dependent 
covariate in Cox regression analysis, individuals with an IPAA carried greater risk of 
graft loss versus both the ileostomy (time adjusted HR: 7.32, 95% CI 1.42 – 37.83, P 
= 0.017) and no colectomy groups (time adjusted hazard ratio [HR]: 3.15, 95% CI 
1.17 – 8.50, P = 0.023).  
 
Between our colectomy groups more specifically, IPAA was more often fashioned 
when the indication for colonic resection was active colitis (Table 1). Nevertheless, 
the negative impact of IPAA on graft survival was retained in a sub-analysis within 
the latter cohort specifically (Figure 4).  
 
The incidence of post-transplant complications is attenuated in patients retaining 
an ileostomy, but not an IPAA 
Hepatic artery thrombosis (44%) and recurrent biliary stricturing disease (37%) 
comprised the principal aetiologies of graft loss in our overall cohort, with lesser 
contributions from primary graft non-function and acute graft rejection (15% and 4%, 
respectively).  
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As such, 25 individual patients developed hepatic artery thrombosis (10%); and 
independently, 75 patients developed recurrent biliary strictures (31%), contributing 
to 12 and 10 incidents of 1
st
 graft loss, respectively. The event rate of hepatic artery 
thrombosis was elevated in the IPAA group by greater than fourfold that of the 
ileostomy group (IR: 2.8 [95% CI: 2.0 – 4.6] vs, 0.6 [95% CI 0.5 – 0.7] per-100-pt.-
yrs., respectively; log-rank P = 0.007); but not significantly different compared with 
the patient cohort retaining an intact colon (IR: 1.5 [1.3 – 1.8] per-100-pt.-yrs.; P = 
0.092). No differences were found in the proportion of donors with hepatic artery 
anomaly across the three groups, although 6 recipients did require formation of an 
aortic conduit (IPAA, n = 1; no colectomy group, n = 5). A list of the anatomical 
variants and arterial reconstruction types performed is provided in Supplementary 
Table 2 and Supplementary Table 3.  
 
Our institution and others have previously reported a lower incidence of recurrent 
biliary stricturing disease post-transplant for patients undergoing colectomy (12–
14,16). In the present cohort, we found that this potentially protective effect was 
confined to patients retaining an end ileostomy (Figure 5A), whereas the incidence of 
recurrent biliary strictures was not significantly different between IPAA and no 
colectomy groups (Figure 5B). Episodes of acute rejection did not significantly 
impact the development of recurrent biliary disease (HR: 1.605, 95% CI: 0.647 – 
1.752, P=0.804), neither posed a risk factor for graft loss overall (HR: 0.913, 95% CI: 
0.409 – 2.036, P=0.823).  
 
No significant differences were seen across our three groups in terms of patient 
mortality, or graft loss/mortality as a combined endpoint (Figure 6). 
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DISCUSSION 
 
In Europe and North America the burden of PSC on liver transplant services is 
substantial, given a critical absence of effective medical therapy. A societal impact is 
also evident given the high frequency with which graft loss occurs relative to other 
aetiologies (15,35). As clinicians we strive to provide the best donor organ possible to 
our patients, as well as identify putative risk factors for loss that sit with the recipient. 
An interesting observation is the fact that persistence of colitis after transplantation 
may increase the risk of biliary disease recurrence (12–14,16), although this does not 
always translate to changes in graft survival. Indeed, many individuals still experience 
graft loss in the absence of recurrent PSC and despite undergoing colectomy (11).  
 
To further understand the clinical course that patients experience, and to offer better 
counselling specifically to those needing colonic resection, we examined the impact 
of colectomy type across a large PSC/UC transplant cohort. In so doing, we identify 
IPAA as a significant risk factor for graft loss, even for patients undergoing 
colectomy prior to transplantation or when the impact of colectomy type was 
determined in time-dependent covariate analysis. Conversely, graft survival was 
maximised in the colectomy group retaining an end ileostomy.  
 
The main aetiologies necessitating re-transplantation in our studied cohort were 
hepatic artery thrombosis or recurrent biliary disease. As discussed, the presence of an 
intact colon has been put forward as a risk factor for the latter (12–14,16), albeit 
inconsistently validated (11,36,37). Herein, we identify that any protective effect 
conferred following colectomy (with regard to recurrent biliary disease) is skewed 
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toward the patient group retaining an end ileostomy, whereas no benefit is evident for 
patients with an IPAA. As patients with PSC and IPAA often develop pouchitis and 
poorer pouch function (23), it is plausible that persistent or recurrent episodes of 
intestinal inflammation also contribute to an elevated risk of thrombotic injury, akin 
to that when the colon is retained (7,12–14,16,38). Although speculative, evidence to 
support this hypothesis includes the fact that our ileostomy group experienced the 
lowest incidence of hepatic artery thrombosis; in addition to findings that show 
persistent subclinical intestinal inflammation in PSC associated colitis (39,40), 
associations between pouchitis and thrombocytosis (41), and heightened platelet 
activation during active IBD (42).  
 
Whilst speculative, our data argues against the fact that an aggressive ‘liver 
phenotype’ post-transplant is driven purely by predisposition toward aggressive IBD. 
This is because colectomy overall, a marker of colitis activity in its own right, was in 
itself not a risk factor for re-transplantation. Instead, the negative impact on graft 
outcome was associated with either (a) retaining an intact colon post-transplant, and 
by proxy, persistence of ulcerative colitis as a comorbidity; or (b) formation of IPAA 
in the event colectomy was performed. Detailing the pathogenic mechanisms of PSC 
and pouchitis are beyond the scope of the current study, but of interest, mucosal 
dysbiosis has been called into question in both conditions (43). Whether unique 
commensal disturbances correlate with risk of allograft recurrence, thromboembolic 
events or actual graft loss, is also an area of ongoing investigation (44). Given the 
increased incidence of hepatic artery thrombosis in patients with PSC and IBD (7,38), 
which we now confirm is relevant to those with IPAA, a dedicated evaluation of 
thrombotic tendency is needed in this at-risk population (45). 
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An early study from the Mayo clinic indicated a 10-year graft loss rate of 12.5% for 
transplanted PSC patients with an IPAA (46). The Cleveland Clinic have also 
published their experience; and in a total cohort of 79 transplanted PSC patients they 
also found an increased frequency of hepatic artery thrombosis (27% in the IPAA 
group vs. 18% in the no colectomy group) although surprisingly none went onto be 
re-transplanted, and a comparative outcomes’ analysis against a control ileostomy 
group was not presented (27). By contrast, ours is also the first study to robustly 
determine the impact of colectomy status and type in a time-dependent outcomes’ 
analysis for patients with PSC/UC and show improved graft survival when patients 
elect to retain an ileostomy.  
 
In selected studies, acute rejection has also been linked to development of recurrent 
biliary disease post-transplantation (15), and it is conceivable that alloreactive 
immune responses may recruit long-lived memory T-cells from the gut implicated 
with the development of PSC prior to transplantation. Alternatively, abrupt changes in 
immunosuppression while treating rejection may trigger immune reconstitution and 
subsequent reactivity to biliary epithelial antigenic epitopes associated with the 
development of recurrent disease. However, links between acute rejection and 
recurrent disease are inconsistently validated; and despite poorer outcomes in our 
IPAA group, acute rejection occurred at a similar frequency to those having an 
ileostomy or without colectomy. Moreover, no causal relationship was identified 
between acute rejection and development of either recurrent biliary disease or graft 
loss overall.  
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The therapeutic arena of IBD continues to evolve, and with regards to PSC/colitis 
specifically, a wealth of attention has focussed in targeting the integrin 7 (47,48). 
Although this strategy may not impact liver biochemistry (47), the potential role in 
attenuating disease progression is of particular interest given that recruitment of 
7+ mucosal lymphocytes are implicated in the pathogenesis of PSC liver disease 
(49), including recurrence post-transplantation for patients with colitis and an intact 
colon (15). 
 
Whilst a single centre report, the Birmingham liver unit contributes 25% of all liver 
transplant activity in the United Kingdom (5). Our transplant database is maintained 
prospectively but we nevertheless lack historical data such as quantifiable IBD 
severity scores, extent of colonic involvement and pharmacological treatment 
regimens; neither have we accrued details on IPAA function and quality of life 
indices, or severity of liver disease at the time colectomy was undertaken. This is 
because the tertiary referral nature of our transplant unit means that for many patients, 
IBD care delivery was undertaken at a different centre. An additional restriction is the 
fact that our IPAA group contains a limited number of patients, precluding 
multivariable analysis of robust statistical power. Unlike reports from other centres 
(21), our cohort was also devoid of an IRA group. This is because in PSC/UC, IRA is 
associated with a >6-fold risk of developing rectal cancer compared to IRA in UC 
alone (28); leading to avoidance in fear of malignant degeneration. A further 
limitation is that our prospectively captured data records did not include incidence or 
severity of ischaemia-reperfusion injury (IRI) specifically, a factor which may have 
reduced graft viability for certain individuals. Nevertheless, when IRI leads to early 
graft loss, this is as a result of primary graft non-function. The latter occurred in a 
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total of 4 patients across our entire study cohort, all within the no colectomy group 
(vs. no patient with an IPAA or ileostomy). Moreover, the greatest risk of IRI is in the 
context of organ donation using marginal grafts, mainly livers donated after 
circulatory death (DCD); whereas all patients within our IPAA group were recipients 
of organ donation after brain death.  
 
We must also be mindful that our prolonged study period parallels the evolving 
indications for liver transplantation. For instance, the Model for End Stage Liver 
Disease (MELD) score was only developed in the year 2000 (50,51), and not captured 
for the few within our cohort transplanted prior to January 1994. A similar caution 
applies to the progressive knowledge that surrounds transplant-related complications. 
Consequently, we evaluated the incidence of all recurrent/non-anastomotic biliary 
strictures collectively, for attributing more specific labels to lesions that developed in 
the early 1990s (for instance, differentiating ischaemic-type biliary lesions from 
recurrent PSC) may neither be correct nor consistent with contemporary definitions 
and imaging modalities (7,13). In any event, the lack of ‘protocol’ 
cholangiographic/angiographic surveillance is caveat across most outcome studies in 
transplantation including our own, and it is conceivable that the sub-clinical incidence 
of vascular events and biliary complications is higher than actually reported.  
 
The decision to undergo pouch formation is largely a surgical consideration led 
by patient choice (52). However, given an era of organ shortage in liver 
transplantation, we advocate that all with PSC who require colorectal resection 
be counselled about potential risks of poorer pouch function compared to UC 
alone (23), and also the relatively increased incidence of graft loss; although we 
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cannot be certain of a definite causal relationship between existing pouch and 
liver transplant failure at this stage. In light of our study findings, the impact of 
IPAA, pouch function and pouchitis on clinical events as relate to the native liver 
in PSC also requires investigation, and represents an area of ongoing research 
activity. Further prospective and independent validation is of the utmost 
importance in these areas, and ideally should proceed via multi-centre 
collaborative networks and across a globally representative patient population 
(3).  
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Table 1: Characteristics of PSC / UC patients undergoing liver transplantation” 
 IPAA 
(n = 21) 
End ileostomy 
(n = 54) 
UC but no colectomy 
(n = 165) 
Male sex  19 (90%) 44 (81%) 112 (68%) 
Recipient age at time of liver transplant, years 41 (34 – 55) 49 (42 – 56) 47 (35 – 59) 
MELD score pre-transplantation** 17 (12 – 27) 16 (11 – 21) 13 (10 – 19) 
Era of transplant    
- 1990 – 2000 8 (38%) 20 (37%) 50 (30%) 
- 2000 – 2010 8 (38%) 21 (39%) 51 (31%) 
- 2010 – 2016 5 (24%) 13 (24%) 64 (39%) 
Organ donation after circulatory death 0 (0%) 2 (4%) 20 (12%) 
Living-related organ donation 0 (0%) 0 (0%) 2 (1%) 
Split liver donation 1 (5%) 3 (6%) 18 (11%) 
Duct-to-duct biliary anastomosis 3 (14%) 8 (15%) 17 (10%) 
Episode of acute rejection 5 (24%) 18 (33%) 53 (32%) 
- Greater than 1 episode of acute rejection 1  2  9  
Age at time of colectomy, years 39 (IQR 33 – 43) 49 (IQR 39 – 58)  
 
 
 
 
 
 
 
 
 
Era of colectomy   
- 1990 – 2000 11 (52%) 15 (28%) 
- 2000 – 2010 6 (29% 22 (41%) 
- 2010 – 2016 4 (19%) 17 (31%) 
Colectomy post liver transplant 7 (33%) 33 (61%) 
Colectomy indication   
- Active colitis 20 (95%) 35 (65%) 
- Dysplasia / neoplasia 1 (5%) 12 (22%) 
- Combination 0 (0%) 4 (7%) 
- Other 0 (0%) 3 (6%) 
Abbreviations:  
IPAA, ileal-pouch anal anastomosis; MELD, model for end-stage liver disease score; UC, ulcerative colitis 
 
*MELD scores not captured for procedures performed prior to January 1994 (n=36/240; n=2, 6 and 28 patients in 
the IPAA, end ileostomy and no colectomy groups, respectively). 
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Figure 1: Clinical outcomes following liver transplantation for primary 
sclerosing cholangitis 
Kaplan-Meier estimates illustrating the incidence of [A] graft loss, [B] patient 
mortality, and [C] graft loss / patient morality as a combined endpoint in our overall 
PSC/colitis cohort undergoing liver transplantation. Incidence rates are presented per 
100-patient-years and the respective 95% confidence intervals. Event-free survival 
rates are calculated using the life-tables method. Time zero is set from the point of 
liver transplantation. 
 
Abbreviations: PSC (primary sclerosing cholangitis), Pt. yrs. (patient years), Pts. at 
risk (patients at risk) 
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Figure 2: Post liver transplant clinical course according to colectomy status 
Kaplan-Meier estimates stratified according to colectomy status for all transplanted 
PSC patients with colitis; specifically for graft loss only [A], mortality only [B] and 
graft loss/mortality as a combined clinical endpoint [C]. Incidence rates are presented 
per 100-patient-years and the respective 95% confidence intervals. Event-free 
survival rates are calculated using the life-tables method. Time zero is set from the 
point of liver transplantation. 
 
Abbreviations: PSC (primary sclerosing cholangitis), Pt. yrs. (patient years), Pts. at 
risk (patients at risk) 
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Figure 3:  Liver graft loss rates following transplantation according to colectomy 
type. 
Kaplan-Meier survival estimates of liver graft loss stratified by colectomy type for all 
transplanted PSC patients with colitis. Incidence rates are presented per 100-patient-
years and the respective 95% confidence intervals. Event-free survival rates are 
calculated using the life-tables method. Time zero is set from the point of liver 
transplantation. Results of the overall log rank test are presented in the graphic. 
Outcome of testing in a pairwise Log rank test are as follows: IPAA vs. the ileostomy 
group; P = 0.005; no colectomy vs. the ileostomy group; P value = 0.044 and IPAA 
vs. no colectomy group, P = 0.1. 
 
Abbreviations: IPAA (ileal pouch anal anastomosis), PSC (primary sclerosing 
cholangitis), Pt. yrs. (patient years), Pts. at risk (patients at risk) 
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Figure 4:  Liver graft loss rates following transplantation in patients undergoing 
colectomy for medically refractory colitis. 
Kaplan-Meier survival estimates of liver graft loss specifically in PSC patients who 
underwent colectomy for medically refractory colitis and stratified by colectomy type. 
Incidence rates are presented per 100-patient-years and the respective 95% confidence 
intervals. Event-free survival rates are calculated using the life-tables method. Time 
zero is set from the point of liver transplantation. 
 
Abbreviations: IPAA (ileal-pouch anal anastomosis), PSC (primary sclerosing 
cholangitis), Pt. yrs. (patient years), Pts. at risk (patients at risk) 
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Figure 5:  Incidence of recurrent biliary strictures post-transplant 
The incidence of recurrent biliary strictures that developed in the absence of hepatic 
artery occlusion is shown for the overall cohort, stratified by colectomy type. Event 
rates are depicted for the no colectomy vs. ileostomy group in [A], and no colectomy 
vs. the IPAA group in [B]. Incidence rates presented per 100-patient-years and the 
respective 95% confidence intervals. Event-free survival rates are calculated using the 
life-tables method. Time zero is set from the point of liver transplantation. 
* 5 / 54 patients in the ileostomy group underwent their colectomy following 
development of a recurrent biliary stricture, and thus re-assigned to the ‘no 
colectomy’ group for this analysis. 
 
Abbreviations: IPAA (ileal-pouch anal anastomosis), PSC (primary sclerosing 
cholangitis), Pt. yrs. (patient years), Pts. at risk (patients at risk) 
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Figure 6:  Combined patient and graft survival rates  
Kaplan-Meier survival estimates of patient mortality [A] and patient mortality / graft 
loss as a combined endpoint [B] stratified by colectomy type for all transplanted PSC 
patients with colitis. Incidence rates are presented per 100-patient-years and the 
respective 95% confidence intervals. Event-free survival rates are calculated using the 
life-tables method. Time zero is set from the point of liver transplantation. 
 
Abbreviations: IPAA (ileal-pouch anal anastomosis), PSC (primary sclerosing 
cholangitis), Pt. yrs. (patient years), Pts. at risk (patients at risk) 
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